nodes	percent_of_prediction	percent_of_DWPC	metapath
Etonogestrel—CYP3A4—bone cancer	0.821	1	CbGaD
Etonogestrel—Ethinyl Estradiol—NR1I2—bone cancer	0.0026	0.471	CrCbGaD
Etonogestrel—ESR1—LKB1 signaling events—ETV4—bone cancer	0.00258	0.0737	CbGpPWpGaD
Etonogestrel—ESR1—Signaling events mediated by HDAC Class II—BCOR—bone cancer	0.00254	0.0726	CbGpPWpGaD
Etonogestrel—PGR—Nuclear Receptors—NR1I2—bone cancer	0.00193	0.0552	CbGpPWpGaD
Etonogestrel—PGR—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.00153	0.0436	CbGpPWpGaD
Etonogestrel—ESR1—Signaling events mediated by HDAC Class II—TUBB2A—bone cancer	0.0012	0.0343	CbGpPWpGaD
Etonogestrel—ESR1—Nuclear Receptors—NR1I2—bone cancer	0.00113	0.0324	CbGpPWpGaD
Etonogestrel—ESR1—Nuclear Receptor transcription pathway—NR1I2—bone cancer	0.000895	0.0256	CbGpPWpGaD
Etonogestrel—PGR—Ovarian Infertility Genes—CDK4—bone cancer	0.000802	0.0229	CbGpPWpGaD
Etonogestrel—PGR—Generic Transcription Pathway—ZNF77—bone cancer	0.000779	0.0223	CbGpPWpGaD
Etonogestrel—CYP3A4—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000747	0.0214	CbGpPWpGaD
Etonogestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.000725	0.0207	CbGpPWpGaD
Etonogestrel—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I2—bone cancer	0.000703	0.0201	CbGpPWpGaD
Etonogestrel—ESR1—Plasma membrane estrogen receptor signaling—GNA11—bone cancer	0.000687	0.0197	CbGpPWpGaD
Etonogestrel—ESR1—Estrogen Receptor Pathway—JUN—bone cancer	0.000624	0.0178	CbGpPWpGaD
Etonogestrel—Levonorgestrel—CYP3A4—bone cancer	0.00061	0.111	CrCbGaD
Etonogestrel—ESR1—FOXM1 transcription factor network—CHEK2—bone cancer	0.000603	0.0172	CbGpPWpGaD
Etonogestrel—ESR1—Regulation of Telomerase—WT1—bone cancer	0.000589	0.0169	CbGpPWpGaD
Etonogestrel—Danazol—CYP3A4—bone cancer	0.000556	0.101	CrCbGaD
Etonogestrel—ESR1—Estrogen signaling pathway—BRAF—bone cancer	0.000543	0.0155	CbGpPWpGaD
Etonogestrel—Ethinyl Estradiol—CYP3A4—bone cancer	0.000514	0.0933	CrCbGaD
Etonogestrel—ESR1—FOXM1 transcription factor network—BRCA2—bone cancer	0.000511	0.0146	CbGpPWpGaD
Etonogestrel—ESR1—Plasma membrane estrogen receptor signaling—IGF1R—bone cancer	0.000501	0.0143	CbGpPWpGaD
Etonogestrel—Norethindrone—CYP3A4—bone cancer	0.000494	0.0897	CrCbGaD
Etonogestrel—Methyltestosterone—CYP3A4—bone cancer	0.00047	0.0852	CrCbGaD
Etonogestrel—ESR1—Generic Transcription Pathway—ZNF77—bone cancer	0.000457	0.0131	CbGpPWpGaD
Etonogestrel—Irritability—Methotrexate—bone cancer	0.000423	0.00306	CcSEcCtD
Etonogestrel—Convulsion—Cisplatin—bone cancer	0.000422	0.00305	CcSEcCtD
Etonogestrel—Mood swings—Methotrexate—bone cancer	0.00042	0.00304	CcSEcCtD
Etonogestrel—Pain in extremity—Epirubicin—bone cancer	0.000415	0.003	CcSEcCtD
Etonogestrel—Myalgia—Cisplatin—bone cancer	0.000414	0.003	CcSEcCtD
Etonogestrel—Anxiety—Cisplatin—bone cancer	0.000413	0.00299	CcSEcCtD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000411	0.00298	CcSEcCtD
Etonogestrel—Hot flush—Doxorubicin—bone cancer	0.00041	0.00297	CcSEcCtD
Etonogestrel—Discomfort—Cisplatin—bone cancer	0.000409	0.00296	CcSEcCtD
Etonogestrel—Increased appetite—Doxorubicin—bone cancer	0.000409	0.00296	CcSEcCtD
Etonogestrel—Migraine—Epirubicin—bone cancer	0.000408	0.00296	CcSEcCtD
Etonogestrel—Affect lability—Epirubicin—bone cancer	0.000408	0.00296	CcSEcCtD
Etonogestrel—Menopausal symptoms—Doxorubicin—bone cancer	0.000407	0.00294	CcSEcCtD
Etonogestrel—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000404	0.0115	CbGpPWpGaD
Etonogestrel—Breast disorder—Methotrexate—bone cancer	0.000401	0.0029	CcSEcCtD
Etonogestrel—Anaphylactic shock—Cisplatin—bone cancer	0.000397	0.00287	CcSEcCtD
Etonogestrel—Oedema—Cisplatin—bone cancer	0.000397	0.00287	CcSEcCtD
Etonogestrel—ESR1—Estrogen signaling pathway—JUN—bone cancer	0.000395	0.0113	CbGpPWpGaD
Etonogestrel—Infection—Cisplatin—bone cancer	0.000395	0.00286	CcSEcCtD
Etonogestrel—Mood swings—Epirubicin—bone cancer	0.000393	0.00284	CcSEcCtD
Etonogestrel—Nervous system disorder—Cisplatin—bone cancer	0.000389	0.00282	CcSEcCtD
Etonogestrel—Skin disorder—Cisplatin—bone cancer	0.000386	0.00279	CcSEcCtD
Etonogestrel—Pain in extremity—Doxorubicin—bone cancer	0.000384	0.00278	CcSEcCtD
Etonogestrel—Asthma—Methotrexate—bone cancer	0.000383	0.00277	CcSEcCtD
Etonogestrel—ESR1—FOXM1 transcription factor network—CDK4—bone cancer	0.000379	0.0108	CbGpPWpGaD
Etonogestrel—Anorexia—Cisplatin—bone cancer	0.000379	0.00274	CcSEcCtD
Etonogestrel—Affect lability—Doxorubicin—bone cancer	0.000378	0.00273	CcSEcCtD
Etonogestrel—Migraine—Doxorubicin—bone cancer	0.000378	0.00273	CcSEcCtD
Etonogestrel—Breast disorder—Epirubicin—bone cancer	0.000375	0.00271	CcSEcCtD
Etonogestrel—PGR—Gene Expression—ZNF77—bone cancer	0.000375	0.0107	CbGpPWpGaD
Etonogestrel—Gastritis—Epirubicin—bone cancer	0.000367	0.00266	CcSEcCtD
Etonogestrel—Mood swings—Doxorubicin—bone cancer	0.000364	0.00263	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Cisplatin—bone cancer	0.000362	0.00262	CcSEcCtD
Etonogestrel—Abdominal distension—Epirubicin—bone cancer	0.000361	0.00261	CcSEcCtD
Etonogestrel—Asthma—Epirubicin—bone cancer	0.000359	0.0026	CcSEcCtD
Etonogestrel—Dysuria—Methotrexate—bone cancer	0.000358	0.00259	CcSEcCtD
Etonogestrel—Paraesthesia—Cisplatin—bone cancer	0.000357	0.00258	CcSEcCtD
Etonogestrel—Upper respiratory tract infection—Methotrexate—bone cancer	0.000356	0.00258	CcSEcCtD
Etonogestrel—Breast disorder—Doxorubicin—bone cancer	0.000347	0.00251	CcSEcCtD
Etonogestrel—Decreased appetite—Cisplatin—bone cancer	0.000345	0.0025	CcSEcCtD
Etonogestrel—Bronchitis—Epirubicin—bone cancer	0.000345	0.0025	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Cisplatin—bone cancer	0.000343	0.00248	CcSEcCtD
Etonogestrel—Infestation NOS—Methotrexate—bone cancer	0.000342	0.00247	CcSEcCtD
Etonogestrel—Infestation—Methotrexate—bone cancer	0.000342	0.00247	CcSEcCtD
Etonogestrel—Depression—Methotrexate—bone cancer	0.000341	0.00247	CcSEcCtD
Etonogestrel—Gastritis—Doxorubicin—bone cancer	0.00034	0.00246	CcSEcCtD
Etonogestrel—Pain—Cisplatin—bone cancer	0.00034	0.00246	CcSEcCtD
Etonogestrel—Dysuria—Epirubicin—bone cancer	0.000335	0.00243	CcSEcCtD
Etonogestrel—Abdominal distension—Doxorubicin—bone cancer	0.000334	0.00242	CcSEcCtD
Etonogestrel—Upper respiratory tract infection—Epirubicin—bone cancer	0.000333	0.00241	CcSEcCtD
Etonogestrel—Asthma—Doxorubicin—bone cancer	0.000332	0.0024	CcSEcCtD
Etonogestrel—Pollakiuria—Epirubicin—bone cancer	0.000331	0.0024	CcSEcCtD
Etonogestrel—ESR1—FOXM1 transcription factor network—RB1—bone cancer	0.000329	0.00942	CbGpPWpGaD
Etonogestrel—Feeling abnormal—Cisplatin—bone cancer	0.000327	0.00237	CcSEcCtD
Etonogestrel—Weight increased—Epirubicin—bone cancer	0.000326	0.00236	CcSEcCtD
Etonogestrel—Weight decreased—Epirubicin—bone cancer	0.000324	0.00235	CcSEcCtD
Etonogestrel—ESR1—Plasma membrane estrogen receptor signaling—MMP2—bone cancer	0.000322	0.00921	CbGpPWpGaD
Etonogestrel—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000322	0.0092	CbGpPWpGaD
Etonogestrel—Infestation NOS—Epirubicin—bone cancer	0.00032	0.00231	CcSEcCtD
Etonogestrel—Infestation—Epirubicin—bone cancer	0.00032	0.00231	CcSEcCtD
Etonogestrel—Bronchitis—Doxorubicin—bone cancer	0.000319	0.00231	CcSEcCtD
Etonogestrel—ESR1—FOXM1 transcription factor network—MMP2—bone cancer	0.000316	0.00904	CbGpPWpGaD
Etonogestrel—Body temperature increased—Cisplatin—bone cancer	0.000314	0.00227	CcSEcCtD
Etonogestrel—Neuropathy peripheral—Epirubicin—bone cancer	0.000313	0.00227	CcSEcCtD
Etonogestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—PTGS2—bone cancer	0.000313	0.00896	CbGpPWpGaD
Etonogestrel—Urinary tract infection—Epirubicin—bone cancer	0.000311	0.00225	CcSEcCtD
Etonogestrel—Dysuria—Doxorubicin—bone cancer	0.00031	0.00225	CcSEcCtD
Etonogestrel—Upper respiratory tract infection—Doxorubicin—bone cancer	0.000308	0.00223	CcSEcCtD
Etonogestrel—Haemoglobin—Methotrexate—bone cancer	0.000308	0.00223	CcSEcCtD
Etonogestrel—Haemorrhage—Methotrexate—bone cancer	0.000307	0.00222	CcSEcCtD
Etonogestrel—Pollakiuria—Doxorubicin—bone cancer	0.000307	0.00222	CcSEcCtD
Etonogestrel—ESR1—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000306	0.00876	CbGpPWpGaD
Etonogestrel—ESR1—ATF-2 transcription factor network—PLAU—bone cancer	0.000305	0.00873	CbGpPWpGaD
Etonogestrel—Pharyngitis—Methotrexate—bone cancer	0.000304	0.0022	CcSEcCtD
Etonogestrel—Urinary tract disorder—Methotrexate—bone cancer	0.000303	0.00219	CcSEcCtD
Etonogestrel—Weight increased—Doxorubicin—bone cancer	0.000302	0.00219	CcSEcCtD
Etonogestrel—Urethral disorder—Methotrexate—bone cancer	0.000301	0.00218	CcSEcCtD
Etonogestrel—Weight decreased—Doxorubicin—bone cancer	0.0003	0.00217	CcSEcCtD
Etonogestrel—Sinusitis—Epirubicin—bone cancer	0.0003	0.00217	CcSEcCtD
Etonogestrel—PGR—Validated nuclear estrogen receptor alpha network—JUN—bone cancer	0.000297	0.00849	CbGpPWpGaD
Etonogestrel—Infestation—Doxorubicin—bone cancer	0.000296	0.00214	CcSEcCtD
Etonogestrel—Infestation NOS—Doxorubicin—bone cancer	0.000296	0.00214	CcSEcCtD
Etonogestrel—Visual impairment—Methotrexate—bone cancer	0.000296	0.00214	CcSEcCtD
Etonogestrel—Hypersensitivity—Cisplatin—bone cancer	0.000293	0.00212	CcSEcCtD
Etonogestrel—Neuropathy peripheral—Doxorubicin—bone cancer	0.00029	0.0021	CcSEcCtD
Etonogestrel—ESR1—ATF-2 transcription factor network—CDK4—bone cancer	0.000289	0.00825	CbGpPWpGaD
Etonogestrel—Haemoglobin—Epirubicin—bone cancer	0.000289	0.00209	CcSEcCtD
Etonogestrel—Rhinitis—Epirubicin—bone cancer	0.000288	0.00208	CcSEcCtD
Etonogestrel—Urinary tract infection—Doxorubicin—bone cancer	0.000288	0.00208	CcSEcCtD
Etonogestrel—Haemorrhage—Epirubicin—bone cancer	0.000287	0.00208	CcSEcCtD
Etonogestrel—Eye disorder—Methotrexate—bone cancer	0.000287	0.00207	CcSEcCtD
Etonogestrel—Hypoaesthesia—Epirubicin—bone cancer	0.000286	0.00207	CcSEcCtD
Etonogestrel—Asthenia—Cisplatin—bone cancer	0.000285	0.00206	CcSEcCtD
Etonogestrel—Pharyngitis—Epirubicin—bone cancer	0.000285	0.00206	CcSEcCtD
Etonogestrel—Urinary tract disorder—Epirubicin—bone cancer	0.000284	0.00205	CcSEcCtD
Etonogestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000282	0.00808	CbGpPWpGaD
Etonogestrel—Connective tissue disorder—Epirubicin—bone cancer	0.000282	0.00204	CcSEcCtD
Etonogestrel—Urethral disorder—Epirubicin—bone cancer	0.000281	0.00204	CcSEcCtD
Etonogestrel—Angiopathy—Methotrexate—bone cancer	0.000278	0.00201	CcSEcCtD
Etonogestrel—Sinusitis—Doxorubicin—bone cancer	0.000278	0.00201	CcSEcCtD
Etonogestrel—Immune system disorder—Methotrexate—bone cancer	0.000277	0.002	CcSEcCtD
Etonogestrel—Visual impairment—Epirubicin—bone cancer	0.000277	0.002	CcSEcCtD
Etonogestrel—Testosterone—CYP3A4—bone cancer	0.000272	0.0494	CrCbGaD
Etonogestrel—Diarrhoea—Cisplatin—bone cancer	0.000272	0.00197	CcSEcCtD
Etonogestrel—Alopecia—Methotrexate—bone cancer	0.000271	0.00196	CcSEcCtD
Etonogestrel—Mental disorder—Methotrexate—bone cancer	0.000269	0.00194	CcSEcCtD
Etonogestrel—Eye disorder—Epirubicin—bone cancer	0.000268	0.00194	CcSEcCtD
Etonogestrel—Erythema—Methotrexate—bone cancer	0.000267	0.00193	CcSEcCtD
Etonogestrel—Malnutrition—Methotrexate—bone cancer	0.000267	0.00193	CcSEcCtD
Etonogestrel—Haemoglobin—Doxorubicin—bone cancer	0.000267	0.00193	CcSEcCtD
Etonogestrel—ESR1—AP-1 transcription factor network—PLAU—bone cancer	0.000266	0.00762	CbGpPWpGaD
Etonogestrel—Rhinitis—Doxorubicin—bone cancer	0.000266	0.00193	CcSEcCtD
Etonogestrel—Haemorrhage—Doxorubicin—bone cancer	0.000266	0.00192	CcSEcCtD
Etonogestrel—Hypoaesthesia—Doxorubicin—bone cancer	0.000264	0.00191	CcSEcCtD
Etonogestrel—Pharyngitis—Doxorubicin—bone cancer	0.000264	0.00191	CcSEcCtD
Etonogestrel—PGR—Generic Transcription Pathway—NR1I2—bone cancer	0.000264	0.00754	CbGpPWpGaD
Etonogestrel—Urinary tract disorder—Doxorubicin—bone cancer	0.000262	0.0019	CcSEcCtD
Etonogestrel—Connective tissue disorder—Doxorubicin—bone cancer	0.000261	0.00189	CcSEcCtD
Etonogestrel—Angiopathy—Epirubicin—bone cancer	0.00026	0.00188	CcSEcCtD
Etonogestrel—Urethral disorder—Doxorubicin—bone cancer	0.00026	0.00188	CcSEcCtD
Etonogestrel—Immune system disorder—Epirubicin—bone cancer	0.000259	0.00188	CcSEcCtD
Etonogestrel—Back pain—Methotrexate—bone cancer	0.000258	0.00187	CcSEcCtD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000258	0.00738	CbGpPWpGaD
Etonogestrel—Visual impairment—Doxorubicin—bone cancer	0.000256	0.00185	CcSEcCtD
Etonogestrel—Alopecia—Epirubicin—bone cancer	0.000254	0.00184	CcSEcCtD
Etonogestrel—Vomiting—Cisplatin—bone cancer	0.000253	0.00183	CcSEcCtD
Etonogestrel—ESR1—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000252	0.0072	CbGpPWpGaD
Etonogestrel—Mental disorder—Epirubicin—bone cancer	0.000252	0.00182	CcSEcCtD
Etonogestrel—ESR1—ATF-2 transcription factor network—RB1—bone cancer	0.000251	0.00718	CbGpPWpGaD
Etonogestrel—Rash—Cisplatin—bone cancer	0.00025	0.00181	CcSEcCtD
Etonogestrel—Dermatitis—Cisplatin—bone cancer	0.00025	0.00181	CcSEcCtD
Etonogestrel—Malnutrition—Epirubicin—bone cancer	0.00025	0.00181	CcSEcCtD
Etonogestrel—Erythema—Epirubicin—bone cancer	0.00025	0.00181	CcSEcCtD
Etonogestrel—Eye disorder—Doxorubicin—bone cancer	0.000248	0.0018	CcSEcCtD
Etonogestrel—Ill-defined disorder—Methotrexate—bone cancer	0.000248	0.00179	CcSEcCtD
Etonogestrel—Flatulence—Epirubicin—bone cancer	0.000246	0.00178	CcSEcCtD
Etonogestrel—Tension—Epirubicin—bone cancer	0.000245	0.00177	CcSEcCtD
Etonogestrel—Nervousness—Epirubicin—bone cancer	0.000243	0.00176	CcSEcCtD
Etonogestrel—ESR1—Plasma membrane estrogen receptor signaling—MMP9—bone cancer	0.000242	0.00692	CbGpPWpGaD
Etonogestrel—Back pain—Epirubicin—bone cancer	0.000242	0.00175	CcSEcCtD
Etonogestrel—Angiopathy—Doxorubicin—bone cancer	0.000241	0.00174	CcSEcCtD
Etonogestrel—Malaise—Methotrexate—bone cancer	0.000241	0.00174	CcSEcCtD
Etonogestrel—ESR1—ATF-2 transcription factor network—MMP2—bone cancer	0.000241	0.00689	CbGpPWpGaD
Etonogestrel—Muscle spasms—Epirubicin—bone cancer	0.00024	0.00174	CcSEcCtD
Etonogestrel—Immune system disorder—Doxorubicin—bone cancer	0.00024	0.00174	CcSEcCtD
Etonogestrel—Nausea—Cisplatin—bone cancer	0.000236	0.00171	CcSEcCtD
Etonogestrel—ESR1—FOXA1 transcription factor network—JUN—bone cancer	0.000235	0.00673	CbGpPWpGaD
Etonogestrel—Alopecia—Doxorubicin—bone cancer	0.000235	0.0017	CcSEcCtD
Etonogestrel—Cough—Methotrexate—bone cancer	0.000233	0.00169	CcSEcCtD
Etonogestrel—Mental disorder—Doxorubicin—bone cancer	0.000233	0.00168	CcSEcCtD
Etonogestrel—Ill-defined disorder—Epirubicin—bone cancer	0.000232	0.00168	CcSEcCtD
Etonogestrel—Convulsion—Methotrexate—bone cancer	0.000231	0.00167	CcSEcCtD
Etonogestrel—Erythema—Doxorubicin—bone cancer	0.000231	0.00167	CcSEcCtD
Etonogestrel—Malnutrition—Doxorubicin—bone cancer	0.000231	0.00167	CcSEcCtD
Etonogestrel—Flatulence—Doxorubicin—bone cancer	0.000228	0.00165	CcSEcCtD
Etonogestrel—Myalgia—Methotrexate—bone cancer	0.000227	0.00165	CcSEcCtD
Etonogestrel—Arthralgia—Methotrexate—bone cancer	0.000227	0.00165	CcSEcCtD
Etonogestrel—Tension—Doxorubicin—bone cancer	0.000227	0.00164	CcSEcCtD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000226	0.00163	CcSEcCtD
Etonogestrel—Malaise—Epirubicin—bone cancer	0.000225	0.00163	CcSEcCtD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—ATF1—bone cancer	0.000225	0.00644	CbGpPWpGaD
Etonogestrel—Discomfort—Methotrexate—bone cancer	0.000225	0.00163	CcSEcCtD
Etonogestrel—Nervousness—Doxorubicin—bone cancer	0.000225	0.00163	CcSEcCtD
Etonogestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—CDK4—bone cancer	0.000224	0.00641	CbGpPWpGaD
Etonogestrel—Back pain—Doxorubicin—bone cancer	0.000224	0.00162	CcSEcCtD
Etonogestrel—Muscle spasms—Doxorubicin—bone cancer	0.000222	0.00161	CcSEcCtD
Etonogestrel—ESR1—Gene Expression—ZNF77—bone cancer	0.00022	0.00629	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000219	0.00627	CbGpPWpGaD
Etonogestrel—Cough—Epirubicin—bone cancer	0.000218	0.00158	CcSEcCtD
Etonogestrel—Anaphylactic shock—Methotrexate—bone cancer	0.000218	0.00158	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—KIT—bone cancer	0.000217	0.00621	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—CHEK2—bone cancer	0.000217	0.00619	CbGpPWpGaD
Etonogestrel—Convulsion—Epirubicin—bone cancer	0.000217	0.00157	CcSEcCtD
Etonogestrel—Infection—Methotrexate—bone cancer	0.000217	0.00157	CcSEcCtD
Etonogestrel—Hypertension—Epirubicin—bone cancer	0.000216	0.00156	CcSEcCtD
Etonogestrel—Ill-defined disorder—Doxorubicin—bone cancer	0.000215	0.00155	CcSEcCtD
Etonogestrel—Nervous system disorder—Methotrexate—bone cancer	0.000214	0.00155	CcSEcCtD
Etonogestrel—Myalgia—Epirubicin—bone cancer	0.000213	0.00154	CcSEcCtD
Etonogestrel—Arthralgia—Epirubicin—bone cancer	0.000213	0.00154	CcSEcCtD
Etonogestrel—Anxiety—Epirubicin—bone cancer	0.000212	0.00153	CcSEcCtD
Etonogestrel—Skin disorder—Methotrexate—bone cancer	0.000212	0.00153	CcSEcCtD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000211	0.00153	CcSEcCtD
Etonogestrel—Discomfort—Epirubicin—bone cancer	0.00021	0.00152	CcSEcCtD
Etonogestrel—Malaise—Doxorubicin—bone cancer	0.000209	0.00151	CcSEcCtD
Etonogestrel—Anorexia—Methotrexate—bone cancer	0.000208	0.0015	CcSEcCtD
Etonogestrel—Oedema—Epirubicin—bone cancer	0.000204	0.00148	CcSEcCtD
Etonogestrel—Anaphylactic shock—Epirubicin—bone cancer	0.000204	0.00148	CcSEcCtD
Etonogestrel—Infection—Epirubicin—bone cancer	0.000203	0.00147	CcSEcCtD
Etonogestrel—Cough—Doxorubicin—bone cancer	0.000202	0.00146	CcSEcCtD
Etonogestrel—Convulsion—Doxorubicin—bone cancer	0.0002	0.00145	CcSEcCtD
Etonogestrel—Nervous system disorder—Epirubicin—bone cancer	0.0002	0.00145	CcSEcCtD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.0002	0.00571	CbGpPWpGaD
Etonogestrel—Hypertension—Doxorubicin—bone cancer	0.0002	0.00144	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000199	0.00144	CcSEcCtD
Etonogestrel—Skin disorder—Epirubicin—bone cancer	0.000198	0.00143	CcSEcCtD
Etonogestrel—Insomnia—Methotrexate—bone cancer	0.000197	0.00143	CcSEcCtD
Etonogestrel—Myalgia—Doxorubicin—bone cancer	0.000197	0.00142	CcSEcCtD
Etonogestrel—Arthralgia—Doxorubicin—bone cancer	0.000197	0.00142	CcSEcCtD
Etonogestrel—Anxiety—Doxorubicin—bone cancer	0.000196	0.00142	CcSEcCtD
Etonogestrel—Paraesthesia—Methotrexate—bone cancer	0.000196	0.00142	CcSEcCtD
Etonogestrel—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000196	0.00141	CcSEcCtD
Etonogestrel—Discomfort—Doxorubicin—bone cancer	0.000195	0.00141	CcSEcCtD
Etonogestrel—Anorexia—Epirubicin—bone cancer	0.000194	0.00141	CcSEcCtD
Etonogestrel—Somnolence—Methotrexate—bone cancer	0.000194	0.0014	CcSEcCtD
Etonogestrel—Dyspepsia—Methotrexate—bone cancer	0.000192	0.00139	CcSEcCtD
Etonogestrel—Decreased appetite—Methotrexate—bone cancer	0.000189	0.00137	CcSEcCtD
Etonogestrel—Oedema—Doxorubicin—bone cancer	0.000189	0.00137	CcSEcCtD
Etonogestrel—Anaphylactic shock—Doxorubicin—bone cancer	0.000189	0.00137	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Methotrexate—bone cancer	0.000188	0.00136	CcSEcCtD
Etonogestrel—Fatigue—Methotrexate—bone cancer	0.000188	0.00136	CcSEcCtD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—TGFBR2—bone cancer	0.000188	0.00537	CbGpPWpGaD
Etonogestrel—Infection—Doxorubicin—bone cancer	0.000187	0.00136	CcSEcCtD
Etonogestrel—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	0.000186	0.00533	CbGpPWpGaD
Etonogestrel—Pain—Methotrexate—bone cancer	0.000186	0.00135	CcSEcCtD
Etonogestrel—ESR1—ATF-2 transcription factor network—JUN—bone cancer	0.000186	0.00532	CbGpPWpGaD
Etonogestrel—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000186	0.00134	CcSEcCtD
Etonogestrel—Nervous system disorder—Doxorubicin—bone cancer	0.000185	0.00134	CcSEcCtD
Etonogestrel—Insomnia—Epirubicin—bone cancer	0.000184	0.00133	CcSEcCtD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—BRCA2—bone cancer	0.000184	0.00525	CbGpPWpGaD
Etonogestrel—Skin disorder—Doxorubicin—bone cancer	0.000183	0.00133	CcSEcCtD
Etonogestrel—Paraesthesia—Epirubicin—bone cancer	0.000183	0.00133	CcSEcCtD
Etonogestrel—PGR—Gene Expression—FUS—bone cancer	0.000183	0.00524	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000182	0.0052	CbGpPWpGaD
Etonogestrel—Somnolence—Epirubicin—bone cancer	0.000181	0.00131	CcSEcCtD
Etonogestrel—Anorexia—Doxorubicin—bone cancer	0.00018	0.0013	CcSEcCtD
Etonogestrel—Feeling abnormal—Methotrexate—bone cancer	0.00018	0.0013	CcSEcCtD
Etonogestrel—Dyspepsia—Epirubicin—bone cancer	0.00018	0.0013	CcSEcCtD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000179	0.00513	CbGpPWpGaD
Etonogestrel—ESR1—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000178	0.0051	CbGpPWpGaD
Etonogestrel—Gastrointestinal pain—Methotrexate—bone cancer	0.000178	0.00129	CcSEcCtD
Etonogestrel—Decreased appetite—Epirubicin—bone cancer	0.000177	0.00128	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Epirubicin—bone cancer	0.000176	0.00127	CcSEcCtD
Etonogestrel—Fatigue—Epirubicin—bone cancer	0.000176	0.00127	CcSEcCtD
Etonogestrel—Constipation—Epirubicin—bone cancer	0.000174	0.00126	CcSEcCtD
Etonogestrel—Pain—Epirubicin—bone cancer	0.000174	0.00126	CcSEcCtD
Etonogestrel—ESR1—Validated nuclear estrogen receptor alpha network—JUN—bone cancer	0.000174	0.00498	CbGpPWpGaD
Etonogestrel—Urticaria—Methotrexate—bone cancer	0.000173	0.00125	CcSEcCtD
Etonogestrel—Body temperature increased—Methotrexate—bone cancer	0.000172	0.00125	CcSEcCtD
Etonogestrel—Abdominal pain—Methotrexate—bone cancer	0.000172	0.00125	CcSEcCtD
Etonogestrel—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000172	0.00124	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—MDM2—bone cancer	0.000171	0.00489	CbGpPWpGaD
Etonogestrel—Insomnia—Doxorubicin—bone cancer	0.000171	0.00124	CcSEcCtD
Etonogestrel—Paraesthesia—Doxorubicin—bone cancer	0.000169	0.00123	CcSEcCtD
Etonogestrel—Feeling abnormal—Epirubicin—bone cancer	0.000168	0.00122	CcSEcCtD
Etonogestrel—Somnolence—Doxorubicin—bone cancer	0.000168	0.00121	CcSEcCtD
Etonogestrel—Gastrointestinal pain—Epirubicin—bone cancer	0.000167	0.00121	CcSEcCtD
Etonogestrel—Dyspepsia—Doxorubicin—bone cancer	0.000166	0.0012	CcSEcCtD
Etonogestrel—ESR1—Regulation of Telomerase—JUN—bone cancer	0.000166	0.00475	CbGpPWpGaD
Etonogestrel—Decreased appetite—Doxorubicin—bone cancer	0.000164	0.00119	CcSEcCtD
Etonogestrel—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000163	0.00118	CcSEcCtD
Etonogestrel—Fatigue—Doxorubicin—bone cancer	0.000163	0.00118	CcSEcCtD
Etonogestrel—ESR1—AP-1 transcription factor network—JUN—bone cancer	0.000162	0.00464	CbGpPWpGaD
Etonogestrel—Urticaria—Epirubicin—bone cancer	0.000162	0.00117	CcSEcCtD
Etonogestrel—Pain—Doxorubicin—bone cancer	0.000161	0.00117	CcSEcCtD
Etonogestrel—Constipation—Doxorubicin—bone cancer	0.000161	0.00117	CcSEcCtD
Etonogestrel—Body temperature increased—Epirubicin—bone cancer	0.000161	0.00117	CcSEcCtD
Etonogestrel—Abdominal pain—Epirubicin—bone cancer	0.000161	0.00117	CcSEcCtD
Etonogestrel—Hypersensitivity—Methotrexate—bone cancer	0.000161	0.00116	CcSEcCtD
Etonogestrel—ESR1—LKB1 signaling events—TP53—bone cancer	0.000158	0.00452	CbGpPWpGaD
Etonogestrel—ESR1—AP-1 transcription factor network—MMP9—bone cancer	0.000158	0.00451	CbGpPWpGaD
Etonogestrel—Asthenia—Methotrexate—bone cancer	0.000156	0.00113	CcSEcCtD
Etonogestrel—Feeling abnormal—Doxorubicin—bone cancer	0.000156	0.00113	CcSEcCtD
Etonogestrel—ESR1—Generic Transcription Pathway—NR1I2—bone cancer	0.000155	0.00442	CbGpPWpGaD
Etonogestrel—Gastrointestinal pain—Doxorubicin—bone cancer	0.000154	0.00112	CcSEcCtD
Etonogestrel—Pruritus—Methotrexate—bone cancer	0.000154	0.00112	CcSEcCtD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	0.000152	0.00435	CbGpPWpGaD
Etonogestrel—Hypersensitivity—Epirubicin—bone cancer	0.00015	0.00109	CcSEcCtD
Etonogestrel—Urticaria—Doxorubicin—bone cancer	0.00015	0.00108	CcSEcCtD
Etonogestrel—Abdominal pain—Doxorubicin—bone cancer	0.000149	0.00108	CcSEcCtD
Etonogestrel—Body temperature increased—Doxorubicin—bone cancer	0.000149	0.00108	CcSEcCtD
Etonogestrel—Diarrhoea—Methotrexate—bone cancer	0.000149	0.00108	CcSEcCtD
Etonogestrel—Asthenia—Epirubicin—bone cancer	0.000146	0.00106	CcSEcCtD
Etonogestrel—ESR1—Regulation of nuclear SMAD2/3 signaling—JUN—bone cancer	0.000144	0.00413	CbGpPWpGaD
Etonogestrel—Pruritus—Epirubicin—bone cancer	0.000144	0.00104	CcSEcCtD
Etonogestrel—Dizziness—Methotrexate—bone cancer	0.000144	0.00104	CcSEcCtD
Etonogestrel—Diarrhoea—Epirubicin—bone cancer	0.00014	0.00101	CcSEcCtD
Etonogestrel—Hypersensitivity—Doxorubicin—bone cancer	0.000139	0.00101	CcSEcCtD
Etonogestrel—Vomiting—Methotrexate—bone cancer	0.000139	0.001	CcSEcCtD
Etonogestrel—Rash—Methotrexate—bone cancer	0.000137	0.000994	CcSEcCtD
Etonogestrel—Dermatitis—Methotrexate—bone cancer	0.000137	0.000993	CcSEcCtD
Etonogestrel—Headache—Methotrexate—bone cancer	0.000137	0.000988	CcSEcCtD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—CDK4—bone cancer	0.000136	0.00389	CbGpPWpGaD
Etonogestrel—Asthenia—Doxorubicin—bone cancer	0.000135	0.00098	CcSEcCtD
Etonogestrel—Dizziness—Epirubicin—bone cancer	0.000135	0.000976	CcSEcCtD
Etonogestrel—Pruritus—Doxorubicin—bone cancer	0.000134	0.000966	CcSEcCtD
Etonogestrel—ESR1—Regulation of Telomerase—EGFR—bone cancer	0.000131	0.00373	CbGpPWpGaD
Etonogestrel—Vomiting—Epirubicin—bone cancer	0.00013	0.000938	CcSEcCtD
Etonogestrel—Nausea—Methotrexate—bone cancer	0.000129	0.000937	CcSEcCtD
Etonogestrel—Diarrhoea—Doxorubicin—bone cancer	0.000129	0.000934	CcSEcCtD
Etonogestrel—Rash—Epirubicin—bone cancer	0.000129	0.000931	CcSEcCtD
Etonogestrel—Dermatitis—Epirubicin—bone cancer	0.000128	0.00093	CcSEcCtD
Etonogestrel—Headache—Epirubicin—bone cancer	0.000128	0.000925	CcSEcCtD
Etonogestrel—ESR1—Signaling by ERBB4—KIT—bone cancer	0.000127	0.00364	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—NR1I2—bone cancer	0.000127	0.00363	CbGpPWpGaD
Etonogestrel—Dizziness—Doxorubicin—bone cancer	0.000125	0.000903	CcSEcCtD
Etonogestrel—Nausea—Epirubicin—bone cancer	0.000121	0.000877	CcSEcCtD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—BRAF—bone cancer	0.00012	0.00344	CbGpPWpGaD
Etonogestrel—Vomiting—Doxorubicin—bone cancer	0.00012	0.000868	CcSEcCtD
Etonogestrel—Rash—Doxorubicin—bone cancer	0.000119	0.000861	CcSEcCtD
Etonogestrel—Dermatitis—Doxorubicin—bone cancer	0.000119	0.00086	CcSEcCtD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—RB1—bone cancer	0.000118	0.00338	CbGpPWpGaD
Etonogestrel—Headache—Doxorubicin—bone cancer	0.000118	0.000855	CcSEcCtD
Etonogestrel—PGR—Signaling by ERBB4—EGFR—bone cancer	0.000117	0.00334	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	0.000113	0.00323	CbGpPWpGaD
Etonogestrel—Nausea—Doxorubicin—bone cancer	0.000112	0.000811	CcSEcCtD
Etonogestrel—ESR1—Gene Expression—FUS—bone cancer	0.000107	0.00307	CbGpPWpGaD
Etonogestrel—ESR1—AP-1 transcription factor network—TP53—bone cancer	0.000107	0.00306	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—MDM2—bone cancer	0.000101	0.00289	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—MDM2—bone cancer	0.0001	0.00287	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—GRM4—bone cancer	9.51e-05	0.00272	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—RGS1—bone cancer	9.51e-05	0.00272	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—EIF2S1—bone cancer	9.37e-05	0.00268	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—JUN—bone cancer	8.77e-05	0.00251	CbGpPWpGaD
Etonogestrel—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	8.51e-05	0.00243	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	8.36e-05	0.00239	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—GRM1—bone cancer	8.25e-05	0.00236	CbGpPWpGaD
Etonogestrel—PGR—Gene Expression—EZH2—bone cancer	8.14e-05	0.00233	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	8.06e-05	0.00231	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—NR1I2—bone cancer	7.45e-05	0.00213	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	7.27e-05	0.00208	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—EGFR—bone cancer	6.9e-05	0.00197	CbGpPWpGaD
Etonogestrel—ESR1—Signaling by ERBB4—EGFR—bone cancer	6.86e-05	0.00196	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—SMO—bone cancer	5.81e-05	0.00166	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Breast Cancer Pathway—TP53—bone cancer	5.79e-05	0.00166	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	5.71e-05	0.00163	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—RGS1—bone cancer	5.58e-05	0.0016	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—GRM4—bone cancer	5.58e-05	0.0016	CbGpPWpGaD
Etonogestrel—CYP3A4—Biological oxidations—GSTP1—bone cancer	5.51e-05	0.00158	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—EIF2S1—bone cancer	5.5e-05	0.00157	CbGpPWpGaD
Etonogestrel—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	5.44e-05	0.00156	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—GNA11—bone cancer	5.32e-05	0.00152	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—ATF1—bone cancer	4.94e-05	0.00141	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—GRM1—bone cancer	4.84e-05	0.00138	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—IL3—bone cancer	4.82e-05	0.00138	CbGpPWpGaD
Etonogestrel—ESR1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	4.8e-05	0.00137	CbGpPWpGaD
Etonogestrel—ESR1—Gene Expression—EZH2—bone cancer	4.78e-05	0.00137	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—TGFBR2—bone cancer	4.12e-05	0.00118	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—IGF1R—bone cancer	3.88e-05	0.00111	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NDUFA12—bone cancer	3.87e-05	0.00111	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—SMO—bone cancer	3.41e-05	0.000976	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—NT5C3A—bone cancer	3.2e-05	0.000916	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—GNA11—bone cancer	3.12e-05	0.000892	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—ATF1—bone cancer	2.9e-05	0.00083	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—IL3—bone cancer	2.83e-05	0.000809	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—KIT—bone cancer	2.81e-05	0.000804	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—BRAF—bone cancer	2.64e-05	0.000756	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TGFBR2—bone cancer	2.42e-05	0.000692	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—IGF1R—bone cancer	2.28e-05	0.000651	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MDM2—bone cancer	2.22e-05	0.000634	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—JUN—bone cancer	1.93e-05	0.000551	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—MMP9—bone cancer	1.87e-05	0.000536	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—KIT—bone cancer	1.65e-05	0.000472	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—BRAF—bone cancer	1.55e-05	0.000444	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—EGFR—bone cancer	1.51e-05	0.000433	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—ENO2—bone cancer	1.4e-05	0.000401	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—DHFR—bone cancer	1.3e-05	0.000372	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MDM2—bone cancer	1.3e-05	0.000372	CbGpPWpGaD
Etonogestrel—PGR—Signaling Pathways—TP53—bone cancer	1.27e-05	0.000363	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GNA11—bone cancer	1.22e-05	0.000348	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—JUN—bone cancer	1.13e-05	0.000323	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—MMP9—bone cancer	1.1e-05	0.000314	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—GSTP1—bone cancer	9.43e-06	0.00027	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—EGFR—bone cancer	8.88e-06	0.000254	CbGpPWpGaD
Etonogestrel—ESR1—Signaling Pathways—TP53—bone cancer	7.46e-06	0.000213	CbGpPWpGaD
Etonogestrel—CYP3A4—Metabolism—PTGS2—bone cancer	4.89e-06	0.00014	CbGpPWpGaD
